COMPOSITIONS AND METHODS USING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Compositions comprising doses of NSAIDs less than 75 mg are provided. As shown herein, these compositions may be used for the treatment and prophylaxis of inflammatory conditions on the mucosa. In particular, acetyl salicylic acid at doses of less than 75 mg is shown to have therapeutic and prophylactic effect on the mucosa coupled without the adverse effects associated with NSAID administration.
1 . A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients, carriers, and/or diluents and one or more non-steroidal anti-inflammatory drugs (NSAID), wherein the total concentration of NSAIDs is less than 75 mg/ml.
2 . The pharmaceutical composition according to claim 1 , wherein said NSAIDs comprise acetylsalicylic acid (ASA).
3 . The pharmaceutical composition according to claim 2 , wherein the concentration of said acetylsalicylic acid is less than 10 mg/ml.
4 . The pharmaceutical composition according to claim 1 , wherein said total concentration of NSAIDs is less than 20 mg/ml.
5 . The pharmaceutical composition according to claim 1 , wherein the total NSAID content of said composition is more than 90% or more than 95% or more than 99% salicylate and derivatives thereof by weight of the NSAID content.
6 - 7 . (canceled)
8 . The pharmaceutical composition according to claim 1 , further comprising lactoferrin and lysozyme.
9 . The pharmaceutical composition according to claim 8 , wherein the weight ratio of said lactoferrin to lysozyme is 1:1 to 1:100.
10 . The pharmaceutical composition according to claim 8 , wherein the weight ratio of lactoferrin and lysozyme to NSAID is from 10:1 to 1:10.
11 . (canceled)
12 . The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition comprises:
a) from 1 to 10 mg/ml of said one or more NSAIDs;
b) from 0.1 to 1 mg/ml of lactoferrin;
c) from 1 to 10 mg/ml of lysozyme;
c) from 10 to 100 mg/ml of glycerol;
e) from 100 to 400 mg/ml of sweetener;
f) from 1 to 20 mg/ml menthol;
g) from 1 to 20 mg/ml carboxymethyl cellulose; and
h) from 1 to 20 mg/ml aloe.
13 . The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition is formulated as a lozenge.
14 . (canceled)
15 . The pharmaceutical composition according to claim 13 , wherein said lozenge comprises from 0.1 to 10 mg of acetylsalicylic acid.
16 . (canceled)
17 . The pharmaceutical composition according to claim 13 , wherein said lozenge comprises:
a) from 1 to 10 mg of said one or more NSAIDs;
b) from 0.1 to 1 mg of lactoferrin;
c) from 1 to 10 mg of lysozyme;
c) from 10 to 100 mg of glycerol;
e) from 100 to 400 mg of sweetener;
f) from 1 to 20 mg menthol;
g) from 1 to 20 mg carboxymethyl cellulose; and
h) from 1 to 20 mg aloe.
18 . The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition is formulated as an oral spray.
19 . A method for the treatment or prophylaxis of sore throat in a subject in need thereof comprising administering the pharmaceutical composition according to claim 1 to the subject in need thereof.
20 . The method according to claim 19 , wherein less than 325 mg of the plurality of NSAIDs are administered in 24 hours.
21 - 22 . (canceled)
23 . A pharmaceutical product comprising:
(a) a body configured to be inserted into an oral passage for dispensing the oral spray composition according to claim 18 ;
(b) a reservoir in fluid communication with said orifice, wherein said oral spray composition is contained in said reservoir;
(c) a pump mechanism capable of expelling said oral spray composition through said orifice in appropriate sized aerosolized droplets; capable of coating the oral mucosa of a user.
24 . (canceled)
25 . A method for the treatment or prophylaxis of sore throat in a subject in need thereof comprising:
a) inserting the portion of the pharmaceutical product according claim 23 configured to be inserted into an oral passage into the oral passage of said subject; and
b) actuating said pump mechanism to administer said oral spray composition to said subject.
26 . The method according to claim 25 , wherein said inserting and actuating steps are repeated at a time point more than 10 minutes after the previous of said administration oral spray composition.
27 . A method for the treatment of sore throat in a subject in need thereof comprising administering less than 75 mg of a plurality of NSAIDs to said throat.
28 - 30 . (canceled)
31 . The method according to claim 19 , wherein said administration has minimal or no effect on the barrier integrity of the mucosa as compared to an otherwise identical mucosa that had not been administered said one or more NSAIDs.